



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

Condensed Interim Consolidated Financial Statements

Condensed Interim Consolidated Statements of Financial Position.....	2
Condensed Interim Consolidated Statements of Changes in Equity.....	3
Condensed Interim Consolidated Statements of Earnings and Comprehensive Income	4
Condensed Interim Consolidated Statements of Cash Flows.....	5
Notes to Condensed Interim Consolidated Financial Statements.....	6



**NOTICE TO THE READER OF THE UNAUDITED CONDENSED
INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

Management's Statement of Responsibility for Financial Information

The condensed interim consolidated financial statements are the responsibility of management and have been prepared in accordance with International Financial Reporting Standards. Where necessary, management has made judgments and estimates of the outcome of events and transactions, with due consideration given to materiality. Management is also responsible for all other information in these condensed interim consolidated financial statements and for ensuring that this information is consistent, where appropriate, with the information and data included in the condensed interim consolidated financial statements.

The Company maintains a system of internal controls to provide reasonable assurance as to the reliability of the financial records and safeguarding of its assets. The condensed interim consolidated financial statements have not been audited by the Company's independent auditor, PricewaterhouseCoopers LLP.

The Board of Directors is responsible for overseeing management in the performance of its responsibilities for financial reporting. The Board exercises its responsibilities through the Audit Committee which comprises three independent directors. The Audit Committee meets from time to time with management and the Company's independent auditor to review the financial statements and matters relating to the audit. The Company's independent auditor has full and free access to the Audit Committee. These condensed interim consolidated financial statements have been reviewed by the Audit Committee, who recommended their approval by the Board of Directors.

(s) Paul Baehr

Paul Baehr
President and Chief Executive Officer

Montréal, Canada
March 21, 2024

(s) Danilo Netto

Danilo Netto, CPA, CA
Director and Chair of the Audit Committee

Montréal, Canada
March 21, 2024



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and July 31, 2023

Condensed Interim Consolidated Statements of Financial Position

In Canadian dollars

	Notes	January 31, 2024 \$	July 31, 2023 \$
Assets			
Current assets			
Cash and cash equivalents		8,692,197	8,547,043
Trade and other receivables	4	1,468,406	1,342,874
Inventories	5	253,671	170,921
Prepaid expenses		89,834	167,016
Total current assets		10,504,108	10,227,854
Non-current assets			
Property, plant, equipment and intangible assets	6	2,167,940	1,960,060
Right-of-use assets	7	1,433,881	1,520,960
Deferred income tax assets		3,122,482	3,122,482
Total assets		17,228,411	16,831,356
Liabilities			
Current liabilities			
Trade and other payables		1,423,822	1,585,245
Current portion of lease liabilities	7	260,838	212,845
Total current liabilities		1,684,660	1,798,090
Non-current liabilities			
Non-current portion of lease liabilities	7	1,312,751	1,426,178
Total liabilities		2,997,411	3,224,268
Equity			
Share capital	11	52,010,388	52,543,063
Contributed surplus		1,377,976	1,081,332
Deficit		(39,157,364)	(40,017,307)
		14,231,000	13,607,088
Total liabilities and equity		17,228,411	16,831,356

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

Consolidated Statements of Changes in Equity

In Canadian dollars

	Notes	Share capital \$	Contributed surplus \$	Deficit \$	Total \$
As at July 31, 2023		52,543,063	1,081,332	(40,017,307)	13,607,088
Net earnings				859,943	859,943
Share repurchase		(532,675)	294,697		(237,978)
Share-based compensation	11		1,947		1,947
As at January 31, 2024		52,010,388	1,377,976	(39,157,364)	14,231,000
 As at July 31, 2022		 52,680,158	 977,881	 (43,910,921)	 9,747,118
Net earnings		-	-	778,540	778,540
Share repurchase		(82,767)	65,199		(17,568)
Share-based compensation		-	6,445	-	6,445
As at January 31, 2023		52,597,391	1,049,525	(43,132,381)	10,514,535

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

Consolidated Statements of Earnings and Comprehensive Income

In Canadian dollars

		For the three-month period ended January 31		For the six-month period ended January 31	
	Notes	2024 \$	2023 \$	2024 \$	2023 \$
Revenues		1,922,000	1,722,070	3,980,206	3,473,641
Cost of sales	8	552,774	560,943	1,034,705	1,095,967
Research and development expenses	8	101,052	223,256	230,184	386,176
Selling, general and administrative expenses	8	1,111,062	812,443	1,950,149	1,304,053
Operating earnings		157,112	125,428	765,168	687,445
Foreign exchange (gain) loss	8	85,412	95,242	(21,525)	9,505
Finance expenses - net	8	(83,700)	(75,300)	(163,500)	(106,053)
Other (income) expenses	8	-	5,453	(15,486)	5,453
Earnings before income taxes		155,400	100,033	965,679	778,540
Provision for income taxes		105,736	-	105,736	-
Net earnings and comprehensive income		49,664	100,033	859,943	778,540
Basic and diluted net earnings per share		0.00	0.00	0.03	0.03

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

Consolidated Statements of Cash Flows

In Canadian dollars

	Notes	For the six-month period ended January 31, 2024 \$	For the six-month period ended January 31, 2023 \$
Cash flows generated from operating activities			
Net earnings		859,943	778,540
Adjustments for non-cash income and expenses			
Depreciation of property, plant, equipment and intangible assets	6	120,150	70,687
Depreciation right-of-use assets	7	147,281	131,502
Share-based compensation		1,947	6,445
Accretion expenses on lease liabilities	7	37,133	33,972
		1,166,454	1,021,146
Changes in non-cash working capital balances			
Increase in trade and other receivables		(125,532)	(50,206)
(Increase) decrease in inventories		(82,750)	12,732
Decrease in prepaid expenses		77,182	77,236
Decrease in trade and other payables		(161,423)	(469,459)
Net changes in non-cash working capital balances		(292,523)	(429,697)
Net cash generated from operating activities		873,931	591,449
Cash flows used in investing activities			
Purchase of property, plant and equipment	6	(328,030)	(582,920)
Net cash used in investing activities		(328,030)	(582,920)
Cash flows used in financing activities			
Share repurchase		(237,978)	(17,568)
Principal payments of leases liabilities	7	(162,769)	(142,369)
Net cash used in financing activities		(400,747)	(159,937)
Net change in cash and cash equivalents		145,154	(151,408)
Cash and cash equivalents at beginning of year		8,547,043	7,641,052
Cash and cash equivalents at end of the quarter		8,692,197	7,489,644

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

Notes to Consolidated Financial Statements

1 General information

IBEX Technologies Inc. / Technologies IBEX Inc. ("IBEX" or the "Company"), through its wholly-owned subsidiaries, manufactures and markets enzymes for biomedical use. IBEX also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research. These unaudited condensed interim consolidated financial statements were authorized for issue by the Board of Directors on **March 21, 2024** and were signed on its behalf.

The Company is a public company listed on the TSX Venture Exchange and is incorporated and domiciled in Canada. The address of its registered office is 5485 Paré Street, Suite 100, Montréal, Québec.

2 Summary of significant accounting policies

Basis of presentation

These unaudited condensed interim consolidated financial statements ("interim financial statements") were prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), and in compliance with International Accounting Standard 34 – Interim Financial Reporting ("IAS 34"). Accordingly, certain information and notes disclosures normally included in the audited annual consolidated financial statements have been omitted or condensed. These interim financial statements should be read in conjunction with the Company's audited annual consolidated financial statements for the year ended July 31, 2023.

The interim financial statements include all adjustments considered necessary by management to fairly state the Company's results of operations, financial position and cash flows. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

Accounting policies

These interim financial statements have been prepared using the same accounting policies as those presented in the Company's audited annual consolidated financial statements for the year ended July 31, 2023.

A number of new standards or amendments to standards and interpretations will be effective for the fiscal year beginning August 1, 2023 or after. The Company does not expect that these new standards or amendments will have a significant impact on its consolidated financial statements.

3 Financial instruments

Currency risk

The Company operates internationally, and its sales are mainly contracted in US dollars. A change in the currency exchange rate between the Canadian dollar and the US dollar could have a material effect on its consolidated earnings and comprehensive income, financial position and cash flows.

The Company's objective in managing its foreign currency risk is to minimize its net exposure to foreign currency cash flows by buying, from time to time, forward foreign exchange contracts to hedge a portion of the exposure of its foreign currency cash flows. Foreign exchange contracts will usually have a maturity of less than two years. As at January 31, 2024, the Company had two forward foreign exchange contracts outstanding. On March 4, 2024, both these contracts were closed out for a net loss of \$3,000.



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

The Company is exposed to foreign currency risk primarily as a result of revenues and expenses denominated in US dollars. Financial instruments denominated in foreign currencies as at January 31, 2024 and July 31, 2023 were as follows:

	January 31, 2024		July 31, 2023	
	CAS	US\$	CAS	US\$
Cash and cash equivalents	2,052,051	1,531,724	1,782,840	1,352,994
Trade and other receivables	949,939	709,068	847,086	642,852
Trade and other payables	41,702	31,128	36,704	27,854

The impact on the Company's (excluding its wholly-owned US subsidiary Bio-Research Products Inc.) financial instruments of a 5% increase in the US dollar exchange rate would be a foreign exchange gain of \$152,185 recorded in net earnings for the six-month period ended January 31, 2024 (July 31, 2023, \$133,332).

Credit risk

Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents, as well as trade and other receivables. Cash and cash equivalents consist of bank balances and money market funds maintained at financial institutions with high credit ratings. Therefore, the Company considers the risk of non-performance for cash and cash equivalents to be low.

The aging of trade receivables as at January 31, 2024 was as follows:

Trade receivables	\$	%
Current	1,061,555	100
Past due 31–90 days	-	-
Over 90 days	-	-
	1,061,555	100

The Company's exposure to credit risk for trade receivables for customers with greater than 10% of the total balance was as follows:

	January 31, 2024	July 31, 2023
	%	%
Customer 1	54	75
Customer 2	11	11

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial liabilities when due. The Company's financial liabilities include its trade and other payables presented on the consolidated statement of financial position, which are due within the next 12 months, and long-term debt. The Company manages liquidity risk by maintaining adequate cash balances to discharge its liabilities when due.



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

The following table details the maturities of the financial liabilities as at January 31, 2024.

	Carrying amount \$	Contractual cash flows \$	Less than 1 year \$	Between 1 and 3 years \$	Between 3 and 5 years \$	More than 5 years \$
Trade and other payables	1,423,822	1,423,822	1,423,822	-	-	-
Lease liabilities ¹	1,573,589	1,824,067	327,681	586,707	597,382	312,297
	2,997,411	3,247,889	1,751,503	586,707	597,382	312,297

1- See Note 7.

Management believes that the Company has sufficient funds to meet its obligations and planned expenditures for the ensuing twelve months as they fall due. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period.

Financial instruments

Except for derivatives, the Company has evaluated the fair value of its financial instruments based on the current interest rate environment, related market values and current pricing of financial instruments with comparable terms. The carrying value of its financial instruments is considered to approximate fair value.

The Company categorizes its financial instruments according to the following three hierarchical levels:

Level 1 – Measurement based on quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 – Valuation techniques based primarily on observable market data; and

Level 3 – Valuation techniques not based primarily on observable market data.

As at January 31, 2024 and July 31, 2023, there are no financial instruments that were accounted for using fair value.

4 Trade and other receivables

	January 31, 2024 \$	July 31, 2023 \$
Trade	1,061,555	902,445
Sales tax	61,869	60,383
Interest receivable	14,699	15,498
SR&ED receivable	330,283	364,548
	1,468,406	1,342,874



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

5 Inventories

	January 31, 2024	July 31, 2023
	\$	\$
Finished goods – Enzymes	220,009	164,586
Finished goods – Arthritis diagnostic kits	8,395	6,335
Work in process – Enzymes	25,267	-
	253,671	170,921

6 Property, plant, equipment and intangible assets

	January 31, 2024	January 31, 2023
	\$	\$
Opening July 31, 2023 and 2022		
Cost	5,172,156	4,164,956
Accumulated depreciation	(3,212,096)	(3,040,651)
Net book amount	1,960,060	1,124,305
Six-month period ended January 31, 2024 and 2023		
Opening net book amount	1,960,060	1,124,305
Additions	328,030	582,920
Depreciation charge	(120,150)	(70,687)
Closing net book amount	2,167,940	1,636,538
Ending January 31, 2024 and 2023		
Cost	5,500,186	4,747,876
Accumulated depreciation	(3,332,246)	(3,111,338)
Net book amount	2,167,940	1,636,538



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

7 Right-of-Use Assets and Lease Liabilities

	January 31, 2024 \$	January 31, 2023 \$
<i>Right-of-Use Assets</i>		
Opening July 31, 2023 and 2022		
Cost	2,206,545	2,140,855
Accumulated depreciation	(685,585)	(593,539)
Net book amount	1,520,960	1,547,316
Six-month period ended January 31, 2024 and 2023		
Opening net book amount	1,520,960	1,547,316
Additions	60,202	59,261
Addition - Termination	(59,262)	(173,565)
Depreciation charge	(147,281)	(131,502)
Depreciation - Termination	59,262	173,565
Closing net book amount	1,433,881	1,475,075
Ending January 31, 2024 and 2023		
Cost	2,207,485	2,026,551
Accumulated depreciation	(773,604)	(551,476)
Net book amount	1,433,881	1,475,075
<i>Lease liabilities</i>		
Opening July 31, 2023 and 2022	1,639,023	1,624,698
Addition	60,202	59,261
Accretion expense	37,133	33,972
Payments	(162,769)	(142,369)
As at January 31, 2024 and 2023	1,573,589	1,575,562
Current portion of lease liabilities	260,838	216,401
Long-term portion of lease liabilities	1,312,751	1,359,161
Closing net book amount	1,573,589	1,575,562



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

8 Expense by nature

	January 31, 2024 \$	January 31, 2023 \$
Salaries and benefits expense	1,674,755	1,509,186
Share-based compensation expense	1,947	6,445
Board compensation	172,527	157,889
Contracts and collaborators	286,626	65,541
Professional fees	288,096	170,521
Shareholders' relation fees	29,234	16,645
Occupancy costs	90,046	71,498
Insurance	49,590	51,708
Royalties	-	18,171
Sales, administration and all other expenses	437,537	503,671
Foreign exchange (gain) loss	(21,525)	9,505
Accretion expense - lease	37,133	33,972
Finance expense	12,980	16,196
Finance revenue	(213,613)	(156,221)
Changes in inventory allocation, work in process and finished goods	(82,751)	12,732
Depreciation of property, plant, equipment and intangible assets	120,150	70,687
Depreciation right-of-use assets	147,281	131,502
Other (income) expense	(15,486)	5,453
	<u>3,014,527</u>	<u>2,695,101</u>

9 Key management compensation

Key management includes the Company's executives and members of the Board of Directors. Compensation awarded to key management included:

	January 31, 2024 \$	January 31, 2023 \$
Salaries, share-based compensation and employee benefits	<u>918,695</u>	<u>1,012,837</u>

As of January 31, 2024 and included in the above, an amount of \$330,812 was paid to key management in respect of the Company's profit sharing plan for the year ended July 31, 2023 (January 31, 2023 – \$438,251).



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

10 Segment information and economic dependence

Reliance on key customers

The Company is highly reliant on sales from a small number of customers. During the six-month period ended January 31, 2024, 75% of its sales derived from its top three customers (July 31, 2023 – 75%)

	January 31, 2024 %	July 31, 2023 %
Customer A	59	55
Customer B	9	13
Customer C	7	7

Industry

The Company operates in one industry segment: the production and sale of diagnostic products.

Geographic information

The Company currently has production facilities in Canada only.

The Company's sales by geographic region for the six-month period ended January 31, 2024, and the year ended July 31, 2023 were as follows:

	January 31, 2024 %	July 31, 2023 %
Canada	10	19
United States	64	62
United Kingdom	9	8
Germany	8	6
Other	9	5
	100	100

11 Share capital

Issued and fully paid

	January 31, 2024		July 31, 2023	
	Number of common shares	Book value \$	Number of common shares	Book value \$
Beginning balance	24,758,644	52,543,063	24,823,244	52,680,158
Share repurchase	(251,000)	532,675	(64,600)	137,095
Ending balance	24,507,644	52,010,388	24,758,644	52,543,063



IBEX Technologies Inc. / Technologies IBEX Inc.
Unaudited Condensed Interim Consolidated Financial Statements
Second Quarter ended January 31, 2024 and 2023

Normal Course Issuer Bid

On July 17, 2023, the Company announced that the TSX Venture Exchange approved the renewal of the Normal Course Issuer Bid (“2024 NCIB”) that was originally launched on July 29, 2022. The 2024 NCIB commenced on August 5, 2023 and will end on the earlier of August 4, 2024 or when the Company completes its maximum purchases under the NCIB. A total of 1,500,000 shares can be repurchased under the 2024 NCIB. As of the date of the financial statements, 64,600 shares were repurchased and cancelled at a cost of \$42,584 for the original 2023 NCIB and 251,000 shares have been repurchased and cancelled for the 2024 NCIB at a cost of \$232,500.

Stock options

Stock options are granted to directors, full-time employees and consultants. The terms and conditions of the grants thereunder are contingent on the market value of the Company’s stock, the discretion of the Board of Directors and regulatory requirements. The number of common shares reserved for issuance under the Company’s stock option plan is 2,400,000. The maximum term permissible under the plan is 10 years. The terms and the vesting privileges are determined at the date of grant. The vesting privileges for the options range from immediate to a three-year vesting term.

The following tables summarize the IBEX stock option plan for the quarter ended January 31, 2024 and the year ended July 31 2023:

	January 31, 2024		July 31, 2023	
	Number of options	Weighted average exercise price \$	Number of options	Weighted average exercise price \$
Beginning balance	1,615,000	0.25	1,615,000	0.25
Granted	-	-	-	-
Expired	-	-	-	-
Ending balance	1,615,000	0.25	1,615,000	0.25

The following table summarizes the IBEX stock options outstanding as at January 31, 2024:

Options outstanding and currently exercisable			
Exercise prices \$	Number outstanding	Number vested and exercisable	Weighted average remaining contractual life (years)
0.14	405,000	405,000	5.98
0.15	300,000	300,000	4.90
0.20	425,000	425,000	3.88
0.24	35,000	35,000	3.22
0.48	450,000	450,000	7.90
	1,615,000	1,615,000	